Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

@article{Mazzu2000ItraconazoleAT,
  title={Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin},
  author={Arthur Mazzu and Kenneth C. Lasseter and E. C. Shamblen and Vipin Agarwal and John T. Lettieri and P Sundaresen},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2000},
  volume={68}
}
3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) are metabolized by distinct pathways that may alter the extent of drug‐drug interactions. Cerivastatin is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8. Atorvastatin is metabolized solely by CYP3A4, and pravastatin metabolism is not well defined. Coadministration of higher doses of these statins with CYP3A4 inhibitors has the potential for eliciting adverse drug‐drug interactions. 
Effect of itraconazole on the pharmacokinetics of rosuvastatin
TLDR
The current trials aimed to examine in vivo the effect of itraconazole on the pharmacokinetics of rosuvastatin. Expand
Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro *
TLDR
Both atorVastatin and fluvastatin inhibit the CYP 3A4‐mediated metabolism of midazolam in vitro, using pooled human liver microsomes. Expand
Role of P‐glycoprotein in Statin Drug Interactions
TLDR
Drug interaction studies involving statins and digoxin support a role for P‐gp, an efflux protein located in the gastrointestinal tract, placenta, kidneys, brain, and liver, and many additional drugs such as diltiazem, verapamil, itraconazoles, ketoconazole, and cyclosporine, interact with statin and are modulators of both CYP3A4 and P‐ gp. Expand
ERSPECTIVES IN CLINICAL HARMACOLOGY rug interactions with lipid-lowering rugs : Mechanisms and clinical relevance
Lipid-lowering drugs, especially 3-hydroxy-3-methylglutaryl–coenzyme A inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic disease. The benefits of statins areExpand
Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance
TLDR
The effects of cyclosporine and gemfibrozil explain the increased plasma statin concentrations and, together with pharmacodynamic factors, the increased risk of myotoxicity when coadministered with statins. Expand
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
TLDR
This review presents a quantitative analysis of the effect of some factors on the pharmacokinetics of statins based on a physiologically based pharmacokinetic model and suggests that model-based prediction is also useful. Expand
Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions
TLDR
The current knowledge base and the complexities of CYP inhibition are summarized and a guide for embarking on prediction of clinical DDIs with particular emphasis on the drug discovery setting is provided. Expand
Controversy surrounding the safety of cerivastatin
TLDR
The noted myotoxicity and subsequent withdrawal of cerivastatin from the worldwide market in August 2001 has demonstrated that the safety of statins is not a class effect and insights into high-risk populations that are more prone to statin-induced myopathy are provided. Expand
Comparative Analysis of Clinical and Non-Clinical Pharmacokinetic Interactions of Statins with Other Drugs
TLDR
Due to several complicating factors such as plasma protein binding, first pass effect, lipophilicity/hydrophilicity, and inter-conversion between acid and lactone forms, further clinical pharmacokinetic interaction studies will be needed to predict the likelihood of drug interactions. Expand
Relationship between Statins Adverse Events and Pharmacokinetic Variables
There are no doubts that statins together with steroids, antibiotics and diuretics are among the most important drugs of the last two centuries. Despite the improvement of the life expectancy,Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Effect of itraconazole on the pharmacokinetics of atorvastatin
TLDR
The aim of this study was to characterize the effect of itraconazole on the pharmacokinetics of atorvastatin, a new HMG‐CoA reductase inhibitor that is metabolized at least in part by CYP3A4. Expand
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
Itraconazole increases the risk of skeletal muscle toxicity of some 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors by increasing their serum concentrations. We studied possibleExpand
The interaction of diltiazem with lovastatin and pravastatin
  • N. Azie, D. Brater, Paula A. Becker, David R. Jones, Stephen D. Hall
  • Chemistry, Medicine
  • Clinical pharmacology and therapeutics
  • 1998
TLDR
Diltiazem, a substrate and a potent inhibitor of cytochrome P4503A enzymes, is commonly coadministered with cholesterol‐lowering agents. Expand
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
TLDR
Itraconazole is a potent inhibitor of CYP3A4, and a possible interaction between these drugs was studied to study the risk of skeletal muscle toxicity following conjunction use of these drugs. Expand
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
TLDR
The effect of erythromycin on the pharmacokinetics of atorvastatin, an inhibitor of HMG‐CoA reductase, was investigated in 12 healthy volunteers and it was found that mean terminal half‐life was similar following each atorVastatin dose. Expand
Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.
To the Editor: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, widely prescribed to treat hypercholesterolemia, are clearly effective and are associated with reductions in ...
Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
  • J. M. Malinowski
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1998
TLDR
Atorvastatin effectively reduces blood lipids and may offer some advantages over other statins, but more studies are needed to clarify its optimal role in pharmacotherapy. Expand
Effect of itraconazole on cerivastatin pharmacokinetics
TLDR
Inhibition of the CYP3A4-mediated M-1 metabolic pathway leads to elevated serum concentrations of cervastatin, cerivastatin lactone and metabolite M-23, resulting in increased concentrations of active HMG-CoA reductase inhibitors. Expand
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
TLDR
It is indicated that cerivastatin is a safe and effective long-term treatment for patients with primary hypercholesterolemia and also suggest that higher doses should be investigated. Expand
Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors
TLDR
This work studied the effect of grapefruit juice on the pharmacokinetics of orally administered simvastatin and found it to be positive for cholesterol‐lowering activity. Expand
...
1
2
3
4
...